Coral Laboratories share news and announcements
BSE: 524506Pharmaceuticals & BiotechnologySmall Cap
Last close ₹494.10down ₹12.85 (2.53%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹506.95.
52-week range of traded prices to 23 Oct 2026
₹360.00Low, 27 Mar 2026₹679.00High, 20 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹177 Cr2,551st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 Oct 2026
- 9.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Sep 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 Oct 2026
- 9.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 Oct 2026
- 7.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Sep 2026
- 0.02
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,855
Coral Laboratories routine notices
172 filed, newest first. Page 4 of 4.
Jun 2019
3 Jun · Routine
May 2019
21 May · Routine
Apr 2019
Feb 2019
12 Feb · Routine
Jan 2019
Oct 2018
Sep 2018
Aug 2018
May 2018
Jan 2018
Oct 2017
May 2017
Jan 2017
Oct 2016
Sep 2016
Aug 2016
May 2016
20 May · Routine
Company’s Code of Conduct for Prevention of Insider Trading as approved and implemented by the Company in pursuance of the SEBI (Prohibition ....